Institutional Member News

• The American Society for Radiation Oncology (ASTRO) recently announced its 2026 class of Fellows, recognizing top leaders and contributors in the field. We are thrilled to highlight that Ke Sheng, PhD, of the University of California, San Francisco (UCSF), was among the esteemed honorees. As UCSF is a proud ANCO member institution, we warmly congratulate Dr. Sheng on this outstanding and well-deserved achievement!

Read More

Corporate Member News

• Johnson & Johnson has updated its Precision Medicine website, a non-branded resource hub offering interactive NGS report guides, multilingual biomarker testing tools, and educational videos to support healthcare providers and patients navigating lung and bladder cancer care.

• The FDA has updated the Prescribing Information for IBRANCE® (palbociclib) on June 24, 2026 to include new data with an expanded indication.

Read More

• The FDA approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. 

Read More

• The FDA approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in first-Line HER2+ Advanced Gastroesophageal Adenocarcinoma.

Read More

FDA Approvals

• FDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer

Read More

• FDA granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

Read More

NCCN Updates

• The National Comprehensive Cancer Network® (NCCN®) recently launched a new Payer Relations Resource Page to clarify how NCCN Guidelines® should be applied during policy development and prior authorization reviews. This tool offers critical context for payer discussions, emphasizing that step therapy within a single line of therapy is not clinically recommended and that NCCN Guidelines are intended to assist clinical decision-making rather than serve as rigid clinical pathways.